With combination data with Azacitidine and preclinical data suggestive of a high degree of synergism between LSD1 inhibition and Venetoclax,135, 153 studying LSD1 inhibition in combination with Azacitidine and Venetoclax is the next natural step in advancing this treatment principle for patients with AML. Here, KDM1A is linked to acute myeloid leukemia.